flutamide has been researched along with Day Blindness in 1 studies
Flutamide: An antiandrogen with about the same potency as cyproterone in rodent and canine species.
| Excerpt | Relevance | Reference |
|---|---|---|
| " Since uninterrupted administration of the antiandrogen is of the outmost importance for the successful therapy of prostatic cancer, the availability of a compound such as flutamide that has no side effect other than those due to hypoandrogenicity should greatly facilitate compliance by the patients and the success of the treatment." | 1.27 | Ocular toxicity of Anandron in patients treated for prostatic cancer. ( Dupont, A; Harnois, C; Labrie, F; Malenfant, M, 1986) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (100.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Harnois, C | 1 |
| Malenfant, M | 1 |
| Dupont, A | 1 |
| Labrie, F | 1 |
1 other study available for flutamide and Day Blindness
| Article | Year |
|---|---|
Ocular toxicity of Anandron in patients treated for prostatic cancer.
Topics: Aged; Androgen Antagonists; Flutamide; Humans; Imidazoles; Imidazolidines; Light; Male; Middle Aged; | 1986 |